AMPK acts as a nutrient sensor within cells, activating during energy shortages to restore balance by reducing energy consumption and enhancing glucose and lipid metabolism.
The anti-aging fame of the diabetes drug metformin is largely due to its ability to activate AMPK. However, as a prescription medication, it remains out of reach for many people. Meanwhile, research and applications of other AMPK activators have been limited. Does this mean we can only watch helplessly as this promising target goes untapped?
Recently, a European research team discovered a novel AMPK activator, O304, which has already entered Phase II human clinical trials. O304 can mimic the benefits of exercise, improving hyperglycemia, insulin resistance, heart function, and physical performance in aged mice. The study was published on November 18 in a prestigious Nature sub-journal [1].
🧬 Why AMPK Activation Matters for Aging
As we age, AMPK activity naturally declines, leading to energy metabolism disorders. Exercise normally activates AMPK by creating a temporary energy and glucose deficit, which brings widespread health benefits.
However, for many older adults, physical limitations prevent them from exercising effectively. To address this, researchers investigated whether O304 could replicate exercise’s effects in the body.
🐁 The Mouse Study: O304 Mimics Exercise Benefits
To focus on aging rather than disease-related confounders, researchers selected aged mice with normal, lean body types. Even in lean mice, aging impairs metabolic function, heart capacity, and vascular flexibility.
After administering O304, they observed:
✅ Improved cardiac performance: Stroke volume, cardiac output, and end-diastolic volume significantly increased.
✅ Better metabolic markers: Heart rate and insulin levels dropped markedly, indicating enhanced heart health and reduced insulin resistance—similar to the effects of exercise.
Intriguingly, O304 even “tricked” the mice’s hearts into believing they were exercising daily, triggering adaptive changes such as increased heart weight and higher myocardial capillary density.
⚠️ The Catch: Corporate Ties and Bioavailability Issues
It’s worth noting that O304 was developed by Swedish biotech company Betagenon, and the study’s corresponding author, Helena Edlund, is a co-founder—raising potential conflicts of interest. Whether these promising findings can translate into practical interventions for humans still requires further validation.
That said, thanks to solid financial and institutional backing, O304’s development has progressed rapidly. It has moved beyond animal studies and is now being tested in human clinical trials for conditions including:
-
Diabetic nephropathy
-
Type 2 diabetes
-
Heart failure
-
Obesity
-
Nonalcoholic fatty liver disease (NAFLD)
So far, its most advanced application is in diabetes treatment. Phase IIa trials showed O304 effectively improved glucose homeostasis, blood pressure, and microvascular perfusion in calf muscles of diabetic patients [2].
However, one limitation is O304’s poor bioavailability in earlier studies. In response, Betagenon developed a new formulation of O304 with improved bioavailability, which has been approved for bridging clinical trials [3].
📊 Figure: Diseases O304 may treat and its potential mechanisms of action (Source: Betagenon website) [4]
🛌 A Future Where “Exercising While Resting” Becomes Reality?
In summary, this study points to an exciting possibility: in the future, we might enjoy the benefits of exercise without actually exercising—“longevity while lying down” could become a reality.